Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1097 participants.
Also called NCT03464019
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,097 participants
- Registry
-
NCT03464019 -
2018-000308-41
-
- Other papers using this trial's data
- Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, France, Germany, Hungary, Netherlands, Poland, Spain
- Registry status
- Terminated
Technical summary
Registry record NCT03464019. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-18 (actual); primary completion 2023-01-20 (actual). Results posted on 2024-07-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).
- Acronym
- NODE-301
- Condition
- Paroxysmal Supraventricular Tachycardia
- Intervention (Drug)
- Etripamil
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Etripamil Test Dose
- Lead sponsor
- Milestone Pharmaceuticals Inc.
- Collaborator
- Medpace, Inc.
- Collaborator
- IQVIA Biotech
Record details
- Record id
cardio:ct-nct03464019- Content hash
5eede922d26613402ad6828098ff0bb4f7b7beb54580c6400984bc184187b34a